Literature DB >> 307007

von Willebrand's disease antigen II. A new plasma and platelet antigen deficient in severe von Willebrand's disease.

R R Montgomery, T S Zimmerman.   

Abstract

Factor VIII-related antigen (VIIIag) is deficient in plasma and platelets of patients with severe von Willebrand's disease. This study reports a second von Willebrand's disease antigen (vWagII), distinct from VIIIag, that is also deficient in the platelets and plasma of patients with severe von Willebrand's disease. VIIIag and vWagII are separable by molecular exclusion chromatography, sucrose density gradient ultracentrifugation, and crossed immunoelectrophoresis. They show reactions of immunologic nonidentity with each other, and thus, do not share a precursor-product relationship. vWagII is released from normal platelets during blood clotting, accounting for a fourfold higher concentration of vWagII in serum over plasma.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 307007      PMCID: PMC372676          DOI: 10.1172/JCI109070

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  Von Willebrand's disease and its correction with human plasma fraction 1-0.

Authors:  I M NILSSON; M BLOMBACK; E JORPES; B BLOMBACK; S A JOHANSSON
Journal:  Acta Med Scand       Date:  1957-11-29

2.  NIH conference. Factor VIII.

Authors: 
Journal:  Ann Intern Med       Date:  1977-05       Impact factor: 25.391

3.  Factor-VIII-related antigen in platelets.

Authors:  M A Howard; D C Montgomery; R M Hardisty
Journal:  Thromb Res       Date:  1974-05       Impact factor: 3.944

4.  A comparison of five different rabbit antisera to factor VIII and the demonstration of a factor VIII related antigen in normal and von Willebrand's disease platelets.

Authors:  S A Shearn; J C Giddings; I R Peake; A L Bloom
Journal:  Thromb Res       Date:  1974-11       Impact factor: 3.944

5.  Immunological characterization of purified anti-haemophilic factor A (factor VIII) which corrects abnormal platelet retention in Von Willebrand's disease.

Authors:  B N Bouma; Y Wiegerinck; J J Sixma; J A Van Mourik; I A Mochtar
Journal:  Nat New Biol       Date:  1972-03-29

Review 6.  The platelet in von Willebrand's disease: interactions with ristocetin and factor VIII.

Authors:  R T Walsh
Journal:  Semin Thromb Hemost       Date:  1975-10       Impact factor: 4.180

7.  Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII.

Authors:  H J Weiss; J Rogers; H Brand
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

8.  Synthesis of factor VIII antigen by cultured guinea pig megakaryocytes.

Authors:  R Nachman; R Levine; E A Jaffe
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

9.  Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand's dissase, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor.

Authors:  T S Zimmerman; O D Ratnoff; A E Powell
Journal:  J Clin Invest       Date:  1971-01       Impact factor: 14.808

10.  Factor VIII coagulant activity and factor VIII-like antigen: independent molecular entities.

Authors:  T S Zimmerman; T S Edgington
Journal:  J Exp Med       Date:  1973-10-01       Impact factor: 14.307

View more
  18 in total

1.  Translational medicine advances in von Willebrand disease.

Authors:  D Lillicrap
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

2.  Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival.

Authors:  Sandra L Haberichter; Michael Balistreri; Pamela Christopherson; Patricia Morateck; Stefana Gavazova; Daniel B Bellissimo; Marilyn J Manco-Johnson; Joan Cox Gill; Robert R Montgomery
Journal:  Blood       Date:  2006-07-11       Impact factor: 22.113

3.  Inheritance and prevalence of von Willebrand's disease severe form in a Brazilian population.

Authors:  R R Fischer; C Lerner; E Bandinelli; A S Fonseca; I Roisenberg
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

4.  Carbohydrate of the factor VIII/von Willebrand factor in von Willebrand's disease.

Authors:  T S Zimmerman; R Voss; T S Edgington
Journal:  J Clin Invest       Date:  1979-11       Impact factor: 14.808

5.  Active release of human platelet factor VIII-related antigen by adenosine diphosphate, collagen, and thrombin.

Authors:  J Koutts; P N Walsh; E F Plow; J W Fenton; B N Bouma; T S Zimmerman
Journal:  J Clin Invest       Date:  1978-12       Impact factor: 14.808

6.  Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).

Authors:  Sandra L Haberichter; Giancarlo Castaman; Ulrich Budde; Ian Peake; Anne Goodeve; Francesco Rodeghiero; Augusto B Federici; Javier Batlle; Dominique Meyer; Claudine Mazurier; Jenny Goudemand; Jeroen Eikenboom; Reinhard Schneppenheim; Jorgen Ingerslev; Zdena Vorlova; David Habart; Lars Holmberg; Stefan Lethagen; John Pasi; Frank G H Hill; Robert R Montgomery
Journal:  Blood       Date:  2008-03-14       Impact factor: 22.113

7.  Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit.

Authors:  J A Dent; M Galbusera; Z M Ruggeri
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

8.  von Willebrand factor binds to platelets and induces aggregation in platelet-type but not type IIB von Willebrand disease.

Authors:  J L Miller; J M Kupinski; A Castella; Z M Ruggeri
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

9.  von Willebrand factor propeptide: biology and clinical utility.

Authors:  Sandra L Haberichter
Journal:  Blood       Date:  2015-07-27       Impact factor: 22.113

10.  Interaction of von Willebrand factor with human platelets in the plasma milieu.

Authors:  J Schullek; J Jordan; R R Montgomery
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.